# A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)

> **NCT00485836** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 392 (actual)

## Conditions studied

- Macular Edema
- Retinal Vein Occlusion

## Interventions

- **DRUG:** Sham injection
- **DRUG:** Ranibizumab injection 0.3 mg
- **DRUG:** Ranibizumab injection 0.5 mg

## Key facts

- **NCT ID:** NCT00485836
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-06
- **Final completion:** 2009-12
- **Target enrollment:** 392 (ACTUAL)
- **Last updated:** 2017-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00485836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00485836, "A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00485836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*